Drug Profile
Vidutolimod - Checkmate Pharmaceuticals
Alternative Names: ARB 1598; CMP-001; CYT 003 QbetaG10; CYT-003; CYT003 PolQb; CYT003 PolQbeta; CYT003-QbG10; Immunodrug™ CYT003-QbG10; IND#18627; QbG10; Virus-like particle-based cancer vaccine - Checkmate Pharmaceuticals; VLP-based cancer vaccine - Checkmate PharmaceuticalsLatest Information Update: 20 Feb 2024
Price :
$50
*
At a glance
- Originator Cytos Biotechnology
- Developer Arbutus Biopharma; Bristol-Myers Squibb; Centre Hospitalier Universitaire Vaudois; Checkmate Pharmaceuticals; Cytos Biotechnology; Genocea Biosciences [CEASED]; Pfizer; University of Pittsburgh
- Class Allergy immunotherapies; Anti-inflammatories; Antiallergics; Antineoplastics; Cancer vaccines; Immunotherapies; Oligonucleotides; Virus-like particle vaccines
- Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Malignant melanoma
- Phase II Head and neck cancer; Merkel cell carcinoma; Squamous cell cancer; Triple negative breast cancer
- Phase I/II Lymphoma; Solid tumours
- No development reported Colorectal cancer; Non-small cell lung cancer
- Discontinued Allergic asthma; Atopic dermatitis; Hepatitis B; Perennial allergic rhinitis; Seasonal allergic rhinitis
Most Recent Events
- 13 Feb 2024 University of Pittsburgh, in collaboration with Checkmate Pharmaceuticals and CellSight Technologies suspends a phase II trial in Malignant melanoma (Late-stage disease, Combination therapy, Neoadjuvant therapy) in USA (Intratumoral) (SC) due to evaluation in process, and pending new trial with similar agents (NCT04401995)
- 05 Feb 2024 Regeneron Pharmaceuticals completes a phase-II trial in Malignant melanoma (Combination therapy, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in USA (Intratumoural) (NCT04698187)
- 19 Jan 2024 Regeneron Pharmaceuticals completes the phase II trial in Head and neck cancer (Metastatic disease, First-line therapy, Combination therapy, Recurrent) in USA (Intratumoural) (NCT04633278)